Tenaya Therapeutics (TNYA) · TN-201
Narrower window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: second half of 2026
In the second half of 2026, one-year Cohort 2 data and two-year Cohort 1 data from MyPEAK-1 are anticipated.
· filed · SEC filing
After
Stated timing: fourth quarter of 2026
Tenaya plans to report additional interim data from the MyPEAK-1 clinical trial in the fourth quarter of 2026.
SEC original · filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/TNYA-tn-201-2026-08-05, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/TNYA-tn-201-2026-08-05
Tenaya Therapeutics (TNYA) pipeline and stated timing · Calendar · Companies A–Z
A Form 10-Q is a company’s quarterly report to the SEC, with unaudited financial statements.